Skip to content
Baret News – Lifestyle
Author:
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
July 28, 2026
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
July 6, 2026
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
May 26, 2026
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
May 22, 2026
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
May 21, 2026
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
May 21, 2026
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
May 20, 2026
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
May 5, 2026
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
April 22, 2026
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
April 14, 2026
1
2
Next Page
→